Eli Lilly And Co (NYSE:LLY) stock fell 1.59% (As on August 8, 11:19:34 AM UTC-4, Source: Google Finance) after the company raised its full-year profit and sales forecast, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk’s, opens new tab Wegovy. However, shares of the U.S. drugmaker fell over 10% to $671.54 in premarket trading after data from its oral weight loss drug, orforglipron, disappointed investors. Orforglipron helped patients lose 12.4% of their weight on average after 72 weeks, less than the 14.9% weight loss seen in a previous trial of Novo’s Wegovy over 68 weeks and below what analysts were expecting. Lilly competes with Danish drugmaker Novo Nordisk, opens new tab in the fast-growing market for weight-loss drugs known as GLP-1 agonists. These drugs are expected to bring in $150 billion in industry-wide revenue over the next decade. Lilly said its share of the U.S. market for incretins, the class of drugs to which diabetes drug Mounjaro and weight-loss drug Zepbound belong, increased to 57% during the quarter. Sales of Mounjaro came in at $5.20 billion for the second quarter, compared with analysts’ expectations of $4.74 billion, according to data compiled by LSEG. Zepbound clocked in sales of $3.38 billion for the quarter. Analysts were expecting sales of $2.95 billion.

LLY in the second quarter of FY25 has reported the adjusted earnings per share of $6.31, beating the analysts’ estimates for the adjusted earnings per share of $5.57, according to LSEG data. The company had reported the adjusted revenue growth of 38 percent to $15.56 billion in the second quarter of FY25, beating the analysts’ estimates for revenue of $14.71 billion.

The company now expects to earn $21.75 to $23 per share on an adjusted basis this year, compared with its previous forecast for a profit of $20.78 to $22.28 per share. The U.S. drugmaker now expects annual sales of $60 billion to $62 billion, compared with its previous forecast of $58 billion and $61 billion. Analysts were expecting revenue of about $60 billion and profit of $21.74 per share for 2025. The pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health—including Mounjaro’s demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease and strong data for the oral incretin, orforglipron, in obesity.